Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.

RMD Open · 2022 · PMC8971359 · PMID 35361691

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients under coimmunosuppression tended to have higher immunogenicity of the third SARS-CoV-2 vaccine compared with those on anti-CD20 monotherapy, but this finding did not reach statistical significance ( online supplemental figure 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.